The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Open accessAbstract
Background Based on preclinical work, we found that combination of poly (ADP-ribose) polymerase (PARP) inhibitors with drugs that inhibit the homologous recombination repair (HRR) pathway (such as PI3K inhibitors) might sensitise HRR-proficient epithelial ovarian cancers to PARP inhibitors. We aimed to assess the safety and identify the recommended phase 2 dose of the PARP inhibitor olaparib in combination with the PI3K inhibitor alpelisib in patients with epithelial ovarian cancer and in patients with breast cancer. Methods In this multicentre, open-label, phase 1b trial following a 3 + 3 dose-escalation design, we recruited patients aged 18 years or older with the following key eligibility criteria: confirmed diagnosis of either recurrent ovarian, fallopian tube, or primary peritoneal cancer of high-grade serous histology; confirmed diagnosis of either recurrent ovarian, fallopian tube, or primary peritoneal cancer of any histology with known germline BRCA mutations; confirmed diagnosis of recurrent breast cancer of triple-negative histology; or confirmed diagnosis of recurrent breast cancer of any histology with known germline BRCA mutations. Additional patients with epithelial ovarian cancer were enrolled in a dose-expansion cohort. Four dose levels were planned: the starting dose level of alpelisib 250 mg once a day plus olaparib 100 mg twice a day (dose level 0); alpelisib 250 mg once a day plus olaparib 200 mg twice a day (dose level 1); alpelisib 300 mg once a day plus olaparib 200 mg twice a day (dose level 2); and alpelisib 200 mg once a day plus olaparib 200 mg twice a day (dose level 3). Both drugs were administered orally, in tablet formulation. The primary objective was to identify the maximum tolerated dose and the recommended phase 2 dose of the combination of alpelisib and olaparib for patients with epithelial ovarian cancer and patients with breast cancer. Analyses included all patients who received at least one dose of the study drugs. The trial is active, but closed to enrolment; follow-up for patients who completed treatment is ongoing. This trial is registered with ClinicalTrials.gov, number NCT01623349. Findings Between Oct 3, 2014, and Dec 21, 2016, we enrolled 34 patients (28 in the dose-escalation cohort and six in the dose-expansion cohort); two in the dose-escalation cohort were ineligible at the day of scheduled study initiation. Maximum tolerated dose and recommended phase 2 dose were identified as alpelisib 200 mg once a day plus olaparib 200 mg twice a day (dose level 3). Considering all dose levels, the most common treatment-related grade 3-4 adverse events were hyperglycaemia (five [16%] of 32 patients), nausea (three [9%]), and increased alanine aminotransferase concentrations (three [9%]). No treatment-related deaths occurred. Dose-limiting toxic effects included hyperglycaemia and fever with decreased neutrophil count. Of the 28 patients with epithelial ovarian cancer, ten (36%) achieved a partial response and 14 (50%) had stable disease according to Response Evaluation Criteria in Solid Tumors 1.1. Interpretation Combining alpelisib and olaparib is feasible with no unexpected toxic effects. The observed activity provides preliminary clinical evidence of synergism between olaparib and alpelisib, particularly in epithelial ovarian cancer, and warrants further investigation. Funding Ovarian Cancer Dream Team (Stand Up To Cancer, Ovarian Cancer Research Alliance, National Ovarian Cancer Coalition), Breast Cancer Research Foundation, Novartis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In cancer cells, the PI3K/AKT pathway may be activated as a survival mechanism in response to the DNA damage caused by olaparib.”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [41]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870 · cited 1×
“Finally, although nausea, fatigue and vomiting were observed in 50% or more of patients, these toxicities were mostly grade 1 and 2, easily manageable, and comparable to those observed with olaparib monotherapy (77% nausea, 63% fatigue and 40% vomiting in the recently reported SOLO1 study(22)).”
ResultSelf-citationNiraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452
Self-citationAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citationPujade-Lauraine, É., Hilpert, F., Weber, B. E., Reuß, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P. O., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,660 · cited 1×
“The median duration of response and median PFS and OS observed in this population were also promising and in line with the results of AURELIA study in platinum resistant ovarian cancer (27) despite the fact that AURELIA involved a significantly less heavily pretreated patient population as it allowed patients with onl…”
ResultSwisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196 · cited 1×
“The promise of PARPis in the management of EOC is tempered, however, by the fact that EOCs with intrinsic, de novo, HRR proficiency respond less than HRR-deficient carcinomas (5, 6).”
BackgroundSelf-citationGelmon, K. A., Tischkowitz, M. D., MacKay, H. J., Swenerton, K. D., Robidoux, A., Tonkin, K. S., Hirte, H. W., Huntsman, D. D., Clemons, M. J., Gilks, C. B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,130 · cited 4×
“The promise of PARPis in the management of EOC is tempered, however, by the fact that EOCs with intrinsic, de novo, HRR proficiency respond less than HRR-deficient carcinomas (5, 6).”
BackgroundInfluentialSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Self-citationFong, P. C. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui‐Roelvink, M., Gourley, C., Grève, J. D., Lubiński, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,022
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Self-citation
Cited by
Sorted by citations
Items 201–264 of 264
Erol, A., Chwiałkowska, K., Zeller, A., Skwarska, A., Ostrowska, A., Sokołowska, G., Doroszko, K., Sidorkiewicz, I., Raczkowska, J., Toczydlowski, D., et al. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110471 · Cited by 3
Николаевна, С. Т., Solov'eva, T. I., Алексахина, С. Н., Bolieva, M. B., Goldberg, V. E., Владимировна, К. М., Меньшиков, К. В., Ryazanov, D. V., Викторович, Ш. А., Станиславовна, Ч. Я., et al. (2022) · Journal of Modern Oncology · doi:10.26442/8151434.2022.1.201435 · Cited by 3
Treatment of Ovarian Clear Cell Carcinoma: A Case of Successful Management With Targeted Therapies
Pence, S., Rath, K. S., & Clements, A. (2025) · Case Reports in Obstetrics and Gynecology · doi:10.1155/crog/1319978 · Cited by 2
“Clinically, a Phase Ib study evaluating treatment with alpelisib and olaparib in germline nonmutated BRCA (gBRCAwt) recurrent ovarian cancer showed an objective response rate (ORR) of 31% which is favorable to the ORR for single-agent olaparib in BRCA-negative or unknown cancers [26].”
Reichenbach, J., Schmid, J., Hierlmayer, S., Zhang, T., Piga, I., Geweniger, S., Fischer, J., Davesar, A., Vasovic, N., Chelariu-Raicu, A., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113999 · Cited by 2
Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2mut breast tumors
Wang, L., Sardella, B., Aronson, E. K., Liu, Z., Li, X., Wulf, G. M., & Heng, Y. J. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-00892-6 · Cited by 3
Self-citationNovel agents to target treatment resistance in ovarian cancer
Washington, C. R., Richardson, D. L., Agyemang, A. F., Odunsi, K. O., & Moore, K. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00008-x · Cited by 2
Decoding evolutionary trajectories of ovarian cancer metastasis
Shimizu, A., & Lengyel, E. R. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.011 · Cited by 2
Bouali, W., Bouali, M., Genç, A. A., & Erk, N. (2025) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1579369 · Cited by 2
Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy
Miller, R. E. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000565 · Cited by 2
Vanacker, H., Romeo, C., & Ray-Coquard, I. L. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000557 · Cited by 2
Zhang, S., Hong, H. I., Mak, V. C. Y., Zhou, Y., Lu, Y., Zhuang, G., & Cheung, L. W. T. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13761 · Cited by 1
“The clinical data of a phase 1b clinical trial investigating the combination of alpelisib and a PARP inhibitor olaparib in ovarian cancer patients have demonstrated encouraging effi-cacy [40].”
Zhao, Y., Hisayoshi, T., Zhang, D., Suzuki, S., Watanabe, T., Kobayashi, A., Guo, Q., Momozawa, Y., Shimokawa, T., Kato, S., et al. (2025) · Cancer Science · doi:10.1111/cas.70081 · Cited by 1
Habiburrahman, M., & Flanagan, J. M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105012 · Cited by 2
Genomics of ovarian cancers and the potential of precision medicine
Jarratt, A., Polidano, J., Scott, C. L., & Barker, H. E. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251396651 · Cited by 1
Chase, D. M., Patton, G., Annavarapu, S., Shi, J., Szamreta, E. A., & Monberg, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1765220 · Cited by 1
The Expanding Role of Pyridine Derivatives as Privileged Scaffolds in Cardiac Ionic Channels
Janapati, Y. K., Cheweti, S., Chidipi, B., Srinivas, M., & Junapudi, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106759 · Cited by 1
Matthew, A., Kumar, R., Mazumder, A., Salahuddin, S., & Bhadauria, H. (2023) · Letters in Organic Chemistry · doi:10.2174/1570178620666230525142927 · Cited by 1
Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
Rogmans, C., Dittrich, J., Hamm, E., Weimer, J. P., Holthaus, D., Arnold, N., Flörkemeier, I., Maass, N., Jansen, P., Dempfle, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-78442-y · Cited by 1
Rimel, B. J., Dockery, L., Randall, L. M., & Moore, K. N. (2020) · Future Oncology · doi:10.2217/fon-2020-0538 · Cited by 1
Stukan, А. I., Goryainova, А. Y., Викторович, Ш. С., Алексеевна, Г. О., Khachmamuk, Z. K., & Durov, V. V. (2022) · Tumors of female reproductive system · doi:10.17650/1994-4098-2022-18-1-54-65 · Cited by 1
Martins, F. C., Couturier, D., de Santiago, I., Sauer, C. M., Vias, M., Angelova, M., Sanders, D. A., Piskorz, A., Hall, J. A. M., Hosking, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.04.325365 · Cited by 1
“Recent clinical trials using combinations of chemotherapeutic agents, PARP inhibitors and/or other targeted therapies in HGSOC and other CIN-driven tumours showed effective response in a subset of patients(31-33).”
BackgroundPersenaire, C., Bitler, B. G., & Corr, B. R. (2024) · medRxiv · doi:10.1101/2024.04.12.24305742 · Cited by 1
Zhang, Y., Xu, M., Yuan, J., Hu, Z., Jiang, J., Huang, J. S., Wang, B., Shen, J., Long, M., Fan, Y., et al. (2024) · eLife · doi:10.7554/elife.99225.1 · Cited by 1
Miller, K. D., Thomas, A., Althouse, S. K., Zang, Y., Conder, E., Burgos, R. S., Schneider, B. P., Ballinger, T. J., Douglas, E., Ansley, K. C., et al. (2025) · medRxiv · doi:10.1101/2025.09.09.25335318 · Cited by 1
Epithelial ovarian cancer: Genomic landscape and evolving precision treatment
DeFazio, A., Gao, B., Mapagu, C., Moujaber, T., & Harnett, P. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00007-8
Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids
Volpari, T., Hebner, J., Aiyar, R. S., & Martin, L. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00080-3
The evolving role of PARP inhibitors in advanced ovarian cancer
Levva, S., Skolariki, A., Sogka, E., Bokas, A., Assi, A., Pispirigou, M. K., & Koliou, P. (2021) · Forum of Clinical Oncology · doi:10.2478/fco-2021-0002
“alpelisib has paved the way to further investigation (123).”
BackgroundThe Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers
Bairi, K. E., Jarroudi, O. A., & Afqir, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-1873-4_3
PARP Inhibitors: Mechanism of Action
Sunada, S., & Miki, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-4521-1_18
Le patriarche de Ferney et les salons féminins de Paris
Menissier, P. (2006) · Travaux de littérature
Deoxyribonucleic Acid Damage Response Defects
Yin, M., Pomerantz, L. D., Vaca, R. A., Grivas, P. D., & Joshi, M. (2022) · Advances in Oncology · doi:10.1016/j.yao.2022.02.006
Belzer, A., Bhullar, S., & Leventhal, J. S. (2022) · Current Dermatology Reports · doi:10.1007/s13671-022-00365-6
Targeted therapy and molecular genetics
Westin, S. N., Sood, A. K., & Coleman, R. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-77684-4.00024-6
Self-citationThe Physiological Mechanisms of Triple Negative Breast Cancer in African American Women
Albert, T. (2023) · Georgetown Medical Review · doi:10.52504/001c.57753
Batalini, F., Xiong, N., Tayob, N., Polak, M. M., Eismann, J., Cantley, L. C., Shapiro, G. I., Adalsteinsson, V. A., Winer, E. P., Konstantinopoulos, P. A., et al. (2023) · doi:10.1158/1078-0432.c.6532290.v1
Self-citationDe, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00002-7
Pessoa, B., Brandao, G., Silva, C. D., Gatof, E. S., Yadav, S., Ernst, B. J., Mina, L. A., Couch, F. J., Wulf, G. M., Tung, N., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2869964/v1
Self-citationPetrella, P. E., Chen, J. W., Ravelo, G. O., & Cosgrove, B. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.28.591568
New Treatments for Chemoresistant Ovarian Cancer: A Systematic Review
Gimenez‐Bonafé, P., & Dols, M. G. (2024) · Revisiones en cáncer · doi:10.20960/revcancer.00086
Pharmacokinetic Interaction Between Olaparib and Regorafenib in an Animal Model
Szkutnik-Fiedler, D., Karbownik, A., Otto, F., Maciejewska, J., Kuźnik, A., Grabowski, T., Wolc, A., Grześkowiak, E., Stanisławiak‐Rudowicz, J., & Szałek, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121575
PARP Inhibitor Counteracts Temozolomide Resistance in Glioblastoma MultiformePreprint
Samarut, É., Tabourel, G., Briand, J., Landais, Y., Gratas, C., Loussouarn, D., Bougras-Cartron, G., Cartron, P., Vallette, F. M., Salaud, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.13.627927
Reichenbach, J., Schmid, J., Hierlmayer, S., Zhang, T., Piga, I., Geweniger, S., Fischer, J., Davesar, A., Vasovic, N., Chelariu-Raicu, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.10.642373
Turaga, S. M., Hembruff, S. L., Savelieff, M. G., Ghosh, A., Puri, R. V., Pathak, H. B., Paradiso, L. J., Myers, T. J., Li, A., & Godwin, A. K. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06152-7
“…have also been clinically evaluated for ovarian cancer patients with wild-type BRCA ; (Matulonis et al. 2017; Westin et al. 2017; Nicum et al. 2024; Konstantinopoulos et al. 2019) interest-ingly, the PI3K inhibitor BKM120 achieved partial remission in half of wild-type BRCA ovarian cancer trial…”
Predictive biomarkers for targeted therapy in daily anatomic pathology for ovarian tumors
Sureka, N., & Zaheer, S. (2025) · Surgical and Experimental Pathology · doi:10.1186/s42047-025-00187-3 · Cited by 2
“…a Phase 1b trial of olaparib and alpelisib in recurrent epithelial ovarian cancer, showing manageable toxicity and promising antitumor activity, especially in patients with BRCA mutations or HRD, supporting further exploration of dual PARP and PI3 K inhibition (Konstantinopoulos et al. 2019).”
Zhang, Y., Xu, M., Yuan, J., Hu, Z., Jiang, J., Sun, Y., Huang, J. S., Wang, Y., Wang, B., Shen, J., et al. (2025) · eLife · doi:10.7554/elife.99225.2
Zhang, Y., Xu, M., Yuan, J., Hu, Z., Jiang, J., Sun, Y., Huang, J. S., Wang, Y., Wang, B., Shen, J., et al. (2025) · eLife · doi:10.7554/elife.99225.3
CldU sensitizes BRCA2 reverse-mutated cells to PARP inhibitors
Zouggari, N., Trugenberger, C., Bois, V. D., Wang, W., Rossetti, G. G., Halazonetis, T. D., & Labidi‐Galy, S. I. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1626301
Mohyuddin, G. R., Aziz, M., Britt, A., Wade, L., Sun, W., Baranda, J., Al-Rajabi, R., Saeed, A., & Kasi, A. (2020) · Figshare · doi:10.6084/m9.figshare.12421322
Dominici, C., Sgarioto, N., Yu, Z., Sesma-Sanz, L., Masson, J., Richard, S., & Raynal, N. J. ‐. (2021) · Figshare · doi:10.6084/m9.figshare.14196636
Mohyuddin, G. R., Aziz, M., Britt, A., Wade, L., Sun, W., Baranda, J., Al-Rajabi, R., Saeed, A., & Kasi, A. (2020) · Figshare · doi:10.6084/m9.figshare.12421328
Nanotechnology for combating chemoresistance in ovarian cancer
Mishra, N., Yadav, M., Saddick, S., Berneau, S., Sharma, J. G., Chandra, R., & Singh, K. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33343-9.00009-0
Current landscape and recent developments of PI3K/AKT/mTOR targeted inhibitors for breast carcinoma
Rana, N., Deval, Singh, H., Garg, A., Monika, Tiwari, R., & Sharma, S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109430
Mohd, O. N., Wang, L., Sardella, B., Jou, D., Wulf, G. M., Slack, F. J., Heng, Y. J., & Doyle, P. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.12.698824
“[ 18 – 21] We have also previously published that the effectiveness of PARP inhibition depends on the tumor immune microenvironment (TME) .”
Self-citationMolecular Insights and Therapeutic Innovations in Cervical Cancer: Emerging Drug Targets
Debnath, A., Singh, R., Mazumder, R., Dua, A., Tyagi, P., & Singh, A. K. (2026) · Advances in pharmacological and pharmaceutical sciences · doi:10.1155/adpp/1452252
Exploring PI3K signalling dynamics in pancreatic cancer
Delgado, C. F. R. (2020) · theses.fr (ABES) · doi:10.70675/6df9a059zc3f1z4997z9de2z34a1d24dfbeb
Zhu, Y., Huang, Y., Song, M., Yang, J., Zhao, J., Tang, Y., Ouyang, D., Yang, C., Chen, Y., Wang, Q., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08735-9
“Our study identi fi es ANXA3 as a biomarker predictive of poor prognosis and lenvatinib resistance in HCC. Collectively, the combined use of Alpelisib and lenvatinib represents a promising therapeutic strategy for lenvatinib-resistant HCC.”
Sensitizing Colorectal Cancer to PARP Inhibitors: Biomarkers, Mechanisms, and Combination Strategies
Elesnawy, M., Masood, E., & Naik, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188127
“…to clinical evaluation in combination with PARPis, although not specifically in CRC. Early-phase studies of olaparib with the PI3K inhibitors buparlisib or alpelisib (NCT01623349) demonstrated the feasibility and preliminary antitumor activity of this approach in breast and ovarian cancers [147].”
Mohd, O. N., Wang, L., Sardella, B., Jou, D., Wulf, G. M., Slack, F. J., Heng, Y. J., & Doyle, P. S. (2026) · eLife · doi:10.7554/elife.112264
Self-citationMohd, O. N., Wang, L., Sardella, B., Jou, D., Wulf, G. M., Slack, F. J., Heng, Y. J., & Doyle, P. S. (2026) · eLife · doi:10.7554/elife.112264.1
Self-citationTargeting PI3Kα with Small Molecules: Progress and Challenges in Tumor Treatment
Jia, W. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48100968
“…PI3K α inhibitors can enhance the sensitivity of PARP inhibitors (such as olaparib) by down-regulating BRCA1/2 expression and inducing homologous recombination repair (HRR) deficiency, so the combination of the two is considered a potentially effective strategy for ovarian cancer treatment [57].”
Liu, S., & Sun, C. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10385-4
Dildabayeva, D., Samarkhanova, D., & Lezina, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209381
“Regarding clinical findings, alpelisib plus olaparib showed preliminary activity in ovarian cancer [109], whereas ipatasertib plus rucaparib did not demonstrate additive or synergistic antitumor activity in previously treated metastatic castration-resistant prostate cancer [110].”
BindingDB Entry 50012286: New drug approvals for 2019: Synthesis and clinical applications.
BindingDB (2022) · UC San Diego · doi:10.7270/q2hd80bx
Metadata
- Authors
- Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., Whalen, C., Curtis, J., Farooq, S., Luo, W., Eismann, J., Buss, M. K., Aghajanian, C., Mills, G. B., Palakurthi, S., Kirschmeier, P., Liu, J., Cantley, L. C., Kaufmann, S. H., Swisher, E. M., D'Andrea, A. D., Winer, E., Wulf, G. M., & Matulonis, U. A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Beth Israel Deaconess Medical Center (US)
- Oregon Health & Science University (US)
- Weill Cornell Medicine (US)
- Mayo Clinic (US)
- University of Washington (US)
- Corresponding author
- Konstantinopoulos, Panagiotis A
- ORCID
- Konstantinopoulos, Panagiotis A
- Birrer, Michael
- Westin, Shannon N
- Cadoo, Karen A
- Shapiro, Geoffrey I
- Mayer, Erica L
- O'Cearbhaill, Roisin E
- Coleman, Robert L
- Kochupurakkal, Bose
- Farooq, Sarah
- Buss, Mary K
- Aghajanian, Carol
- Mills, Gordon B
- Palakurthi, Sangeetha
- Liu, Joyce
- Cantley, Lewis C
- Kaufmann, Scott H
- Swisher, Elizabeth M
- Winer, Eric
- Wulf, Gerburg M
- Matulonis, Ursula A
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 20
- Issue
- 4
- Pages
- 570-580
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7025391
- OpenAlex
- W2921991537
- Cited by
- 263
- References
- 33
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 33 · 2023: 38 · 2022: 48 · 2021: 46 · 2020: 38 · 2019: 17
- FWCI
- 15.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Breast Cancer Research Foundation
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- olaparib, alpelisib, PI3K inhibitors, PARP inhibitors, epithelial ovarian cancer, breast cancer, triple-negative breast cancer, homologous recombination repair, BRCA mutations, high-grade serous ovarian cancer, combination therapy, maximum tolerated dose, recommended phase 2 dose, drug safety, dose escalation, dose expansion, recurrent cancer, PARP inhibitor resistance
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Carcinoma, Ovarian Epithelial, Phosphoinositide-3 Kinase Inhibitors, Aged, Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Female, Humans, Middle Aged, Mutation, Ovarian Neoplasms, Phthalazines, Piperazines, Thiazoles, Genome, Human, Treatment Outcome, Maximum Tolerated Dose, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
